2017 Endocrine Fellows Series: Type 1 Diabetes Care and Management
2017 Endocrine Fellows Series: Type 1 Diabetes Care and Management
Tuesday, March 28, 2017– Rosen Centre Hotel
Wednesday, March 29, 2017– Thursday, March 30, 2017
Hyatt Regency Orlando
The fourth annual Endocrine Fellows Series: Type 1 Diabetes Care and Management is a live CME-certified conference of pediatric and adult endocrine fellows held prior to ENDO 2017 (April 1- 4, 2017) in Orlando, FL. For details on the current and future programs, visit endocrine.org/t1dmfellows.
This activity is supported by educational grants from The Leona M. and Harry B. Helmsley Charitable Trust, Lilly USA, LLC, and Medtronic Diabetes.
Target Audience
This continuing medical education activity should be of substantial interest to pediatric and adult endocrine fellows.
Learning Objectives
Upon completion of this educational activity, participants will be able to (or better able to):
- Differentially diagnose T1D in youth and assess the familial risk of developing T1D
- Utilize patient education and counseling to motivate patients and their caregivers and promote adherence
- Apply current clinical information to set appropriate blood glucose targets taking into consideration a patient’s lifestyle, age and condition
- Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
- Explain the neurological consequences of hypoglycemia and hyperglycemia and recognize potential causes
- Recognize special considerations in the management of diabetes in a trauma or in-patient setting
- Discuss the important of individualized nutrition plans and goals for patients with T1D
- Discuss the potential risks and benefits associated with emerging therapies for diabetes
Additional Information
Program Directors
Irl B. Hirsch, MD; University of Washington
Linda Siminerio, PhD; University of Pittsburgh Diabetes Institute
Presenters
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Timothy S Bailey, MD: Consultant, Bayer, BD, Calibra, Lilly, Medtronic, Novo Nordisk, sanofi; Researcher, Versartis, Yofimeter; Speaker, Insulet, Medtronic, Novo Nordisk, sanofi
Bruce A. Buckingham, MD: Advisory Board Member, Animas, Halozyme, Novo Nordisk, Sanofi; Advisory Board Member and Investigator, Convatec, Medtronic, Tandem; Investigator, Bayer, Dexcom
Mark A. Clements, MD: Advisory Group Member, Glooko/Diasend
Robert H. Eckel, MD: Consultant, Merck & Co. Novo Nordisk, Consultant; Sanofi; Independent Contractor, UniQure; Researcher, Ionis
Alison B. Evert, MS: Medical Advisory Board Member, Seseonice
Carla J. Greenbaum, MD: Consultant, Bristol-Myers Squibb, Pfizer, Inc.; Principal Investigator, Jansen Pharmaceuticals, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbott laboratories, Roche Diagnostics, Intarcia, Valeritas
Janet B. McGill, MD: Advisory Group Member, Jansen Pharmaceuticals, Merck & Co.; Committee Member, Boehringer-Ingelheim; Speaker, Jansen Pharmaceuticals
William H. Polonsky, PhD: Consultant, Abbott Laboratories, Astra Zeneca, Dexcom, Eli Lilli & Company, Novo Nordisk, Roche Diagnostics
Guillermo E. Umpierrez, MD: Consultant, Ad Hoc, Sanofi; Principal Investigator, Astra Zeneca, Merck & Co., Sanofi
The faculty reported the no relevant financial relationship: Roy W Beck, MD; Luisa A Duran, MD; Margaret S. Eckel; Peter J. Eckel; James S. Hirsch; Michael Riddell, MD; Desmond A Schatz, MD; Sandra Sobel, MD
The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
Available Credit
- 16.50 AMA PRA Category 1 Credits™
- 16.50 CME Certificate of Participation